ライフサイエンスコーパス: canarypox virus

1 p a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB)

2 cells, might be immunogenic, we studied how canarypox virus (ALVAC) interacts with primate antigen-p

3 We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-b

4 ge with attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the C

5 oxviruses, including vaccinia virus (VV) and canarypox virus (ALVAC), do not indiscriminately infect

6 We studied (i) the interaction between canarypox virus and DCs and (ii) the T-cell responses in

7 ature DCs resisted the cytopathic effects of canarypox virus and elicited strong effector CD8+ T-cell

8 pro, and env coding sequences was placed in canarypox virus and MVA vector backbones in order to dir

9 identified homologs found in the fowlpox and canarypox viruses and the previously cloned mammalian DN

10 teins produced by African swine fever virus, Canarypox virus, and Herpes simplex virus to promote eIF

11 Avipoxviruses, such as canarypox virus, are replication deficient in mammalian

12 sted in humans utilized a strategy combining canarypox virus-based vector (ALVAC) together with an en

13 Here we show that the canarypox virus-based vector ALVAC induced distinct syst

14 ross mucosal barriers, a randomized trial of canarypox virus-based vectors was conducted in 84 indivi

15 sponses were still detectable 4 months after canarypox virus boost in immunized mice.

16 e responses to HCV DNA prime and recombinant canarypox virus boost were also studied with the above c

17 t 10 months postimmunization (8 months after canarypox virus boost), the protection in HCV DNA prime/

18 At 8 weeks after a canarypox virus boost, the DNA prime/canarypox virus boo

19 s higher than that observed in HCV DNA prime/canarypox virus boost-immunized mice.

20 after a canarypox virus boost, the DNA prime/canarypox virus boosting regimen induced potent cellular

21 nt the genomic sequence, with analysis, of a canarypox virus (CNPV).

22 nded in the avipoxviruses (31 in FWPV; 51 in canarypox virus [CNPV], representing 15% of the total ge

23 lizing antibody and CD4+ T cell help, a live canarypox virus construct expressing gp120, transmembran

24 We also evaluated canarypox virus containing the same HCV genes as a means

25 have determined the crystal structure of the canarypox virus (CPV) resolvase.

26 rotein 1 (PkMSP1p42), as well as recombinant canarypox viruses encoding the four antigens (ALVAC-4).

27 ons of vCP1521 ALVAC (attenuated recombinant canarypox virus expressing HIV group-specific antigen, p

28 ts who were vaccinated with live recombinant canarypox virus expressing human immunodeficiency virus

29 In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV ga

30 201(+) monkeys vaccinated with a recombinant canarypox virus-HIV-1 env construct also demonstrated p4

31 2 months postimmunization, the HCV DNA prime/canarypox virus-immunized mice showed a complete reducti

32 own to be greater than that from recombinant canarypox virus in the mammalian cell lines and in the p

33 cted cells to levels equal to those found in canarypox virus-infected cells.

34 Furthermore, canarypox virus-infected DCs were >30-fold more efficien

35 Most strikingly, canarypox virus-infected DCs were directly able to stimu

36 Several canarypox virus recombinants expressing human or murine

37 o enhance these responses would be to target canarypox virus to professional antigen-presenting cells

38 Canarypox viruses undergo abortive replication in mammal

39 after either systemic or mucosal delivery of canarypox virus vaccine.

40 ients of a vaccine consisting of recombinant canarypox virus vCP205 and recombinant gp120(SF2).

41 was found to be more profound with the empty canarypox virus vector than with MVA.

42 ction, we administered vaccines containing a canarypox virus vector, vCP1452, with HIV-1 genes encodi

43 -cell responses induced by DCs infected with canarypox virus vectors containing HIV-1 genes.

44 Recombinant canarypox virus vectors containing human immunodeficienc

45 refore, these results suggest that targeting canarypox virus vectors to mature DCs could potentially

46 HIV-1-specific (vCP 205) and rabies (vCP 65) canarypox virus vectors were delivered systemically and/

47 the doses and routes of administration used, canarypox virus was not an effective mucosal immunogen.

48 of vaccinia virus and in the ALVAC strain of canarypox virus, which does not productively replicate i